As a fast growing pharmaceutical company, mainly active in the animal health industry, Huvepharma has defined gut health as a crucial factor in poultry production.

Gut health can be disturbed by coccidiosis - a well-known parasitic disease - by its (sub) clinical presence, it can decrease the overall production performance and have a big economic impact. The cost of coccidiosis can be estimated to around eight to 10 Euro-cents per bird.

Through continuous investments in research and development and registrations, Huvepharma takes its long-term responsibility to strengthen its coccidiostat expertise in further extending the existing EU product portfolio (Sacox®, Coxidin®, Stenorol®, Clinacox®). Without a healthy and optimal performing intestinal tract, treatment costs will increase and the uptake of nutrients and growth will be limited, as a consequence - production performance and profitability will drop as well.

To optimise the gut health and to maximise performance, the company advises to rotate more between different products (ionophores and/or chemicals) to maintain the needed sensitivity against all used coccidiostats.

More frequent rotations, combined with vaccination and clean-up programmes are helping to keep the infection pressure low and improve the chicken’s gut health.

Huvepharma stays one step ahead of coccidiosis by the means of custom-made technical support and advice, continuous monitoring and evaluation of new field isolates, coccidiosis workshops and lesion score training.

By keeping coccidiosis under control, Huvepharma adds great value to your business.

Talk to Huvepharma at VIV Europe 2014 in Utrecht on 20 to 22 May, Booth C 040/ Hall 10.

Contact Details

Web: www.huvepharma.com - E-mail: [email protected].